Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rituximab.

S V Onrust1, H M Lamb, J A Balfour

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 10, 1999
PubMed
Summary
This summary is machine-generated.

Rituximab effectively depletes B lymphocytes in patients with relapsed indolent lymphoma, showing significant clinical response rates. While most adverse events are mild, careful monitoring is needed for potential infusion-related reactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Rituximab is a monoclonal antibody targeting the CD20 antigen on B lymphocytes.
  • It induces cell death through antibody-dependent cell- and complement-mediated cytotoxicity.
  • B-cell depletion is a key mechanism in treating certain hematologic malignancies.

Purpose of the Study:

  • To evaluate the efficacy and safety of rituximab in patients with relapsed indolent lymphoma.
  • To assess the duration of B-cell depletion and recovery following rituximab treatment.
  • To compare response rates in different subtypes of indolent lymphoma.

Main Methods:

  • Administration of 4 doses of rituximab (375 mg/m2) weekly.
  • Monitoring of peripheral B lymphocyte counts before, during, and after treatment.

Related Experiment Videos

  • Assessment of clinical response rates in non-comparative trials.
  • Documentation and analysis of adverse events.

    • Main Results:

    • Rituximab reduced peripheral B lymphocyte counts by approximately 90% within 3 days.
    • B-cell depletion persisted for 6 months, with recovery by 9-12 months post-treatment.
    • Overall clinical response rates were 46-48%, with higher rates in follicular lymphoma (56-60%) vs. small lymphocytic disease (13-15%).
    • 85-94% of patients experienced adverse events, mostly mild to moderate (90%).
    • Infusion-related flu-like symptoms occurred in 50-87%, with severe cytokine release syndrome in 10%.

    Conclusions:

    • Rituximab demonstrates significant efficacy in relapsed indolent lymphoma, particularly follicular lymphoma.
    • The drug induces profound and prolonged B-cell depletion.
    • While generally well-tolerated, infusion-related reactions require monitoring and management.